| For: | Dimitroulopoulos D, Xinopoulos D, Tsamakidis K, Zisimopoulos A, Andriotis E, Panagiotakos D, Fotopoulou A, Chrysohoou C, Bazinis A, Daskalopoulou D, Paraskevas E. Long acting octreotide in the treatment of advanced hepatocellular cancer and overexpression of somatostatin receptors: Randomized placebo-controlled trial. World J Gastroenterol 2007; 13(23): 3164-3170 [PMID: 17589893 DOI: 10.3748/wjg.v13.i23.3164] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v13/i23/3164.htm |
| Number | Citing Articles |
| 1 |
|
| 2 |
Marcello Maida, Giuseppe Cabibbo, Giuseppe Brancatelli, Chiara Genco, Nicola Alessi, Claudio Genova, Piero Romano, Maurizio Raineri, Antonello Giarratano, Massimo Midiri, Calogero Cammà. Assessment of Treatment Response in Hepatocellular Carcinoma: A Review of the Literature. Future Oncology 2013; 9(6) doi: 10.2217/fon.13.33
|
| 3 |
Jia Liu, Thomas Mittendorf, J.-Matthias von der Schulenburg. A Structured Review and Guide Through Studies on Health-Related Quality of Life in Kidney Cancer, Hepatocellular Carcinoma, and Leukemia. Cancer Investigation 2010; 28(3) doi: 10.3109/07357900903287022
|
| 4 |
M Caraglia, G Giuberti, M Marra, R Addeo, L Montella, M Murolo, P Sperlongano, B Vincenzi, S Naviglio, S Del Prete, A Abbruzzese, P Stiuso. Oxidative stress and ERK1/2 phosphorylation as predictors of outcome in hepatocellular carcinoma patients treated with sorafenib plus octreotide LAR. Cell Death & Disease 2011; 2(4) doi: 10.1038/cddis.2011.34
|
| 5 |
Claudia Pivonello, Maria Cristina De Martino, Mariarosaria Negri, Gaia Cuomo, Federica Cariati, Francesco Izzo, Annamaria Colao, Rosario Pivonello. The GH-IGF-SST system in hepatocellular carcinoma: biological and molecular pathogenetic mechanisms and therapeutic targets. Infectious Agents and Cancer 2014; 9(1) doi: 10.1186/1750-9378-9-27
|
| 6 |
Chiun Hsu, Ying-Chun Shen, Chia-Chi Cheng, Fu-Chang Hu, Ann-Lii Cheng. Geographic difference in survival outcome for advanced hepatocellular carcinoma: Implications on future clinical trial design. Contemporary Clinical Trials 2010; 31(1) doi: 10.1016/j.cct.2009.08.002
|
| 7 |
Adam C. Yopp, William R. Jarnagin. Randomized Clinical Trials in Hepatocellular Carcinoma. Surgical Oncology Clinics of North America 2010; 19(1) doi: 10.1016/j.soc.2009.09.012
|
| 8 |
Ujendra Kumar. Somatostatin and Somatostatin Receptors in Tumour Biology. International Journal of Molecular Sciences 2023; 25(1) doi: 10.3390/ijms25010436
|
| 9 |
Argyrios Periferakis, Georgios Tsigas, Aristodemos-Theodoros Periferakis, Carla Mihaela Tone, Daria Alexandra Hemes, Konstantinos Periferakis, Lamprini Troumpata, Ioana Anca Badarau, Cristian Scheau, Ana Caruntu, Ilinca Savulescu-Fiedler, Constantin Caruntu, Andreea-Elena Scheau. Agonists, Antagonists and Receptors of Somatostatin: Pathophysiological and Therapeutical Implications in Neoplasias. Current Issues in Molecular Biology 2024; 46(9) doi: 10.3390/cimb46090578
|
| 10 |
Brian I. Carr, Srikanth Nagalla, Ravit Geva. Hepatocellular Carcinoma. 2016; doi: 10.1007/978-3-319-34214-6_33
|
| 11 |
Aldona Kasprzak, Agnieszka Geltz. The State-of-the-Art Mechanisms and Antitumor Effects of Somatostatin in Colorectal Cancer: A Review. Biomedicines 2024; 12(3) doi: 10.3390/biomedicines12030578
|
| 12 |
Maximilian Schöniger-Hekele, Joachim Kettenbach, Markus Peck-Radosavljevic, Christian Müller. Octreotide treatment of patients with hepatocellular carcinoma - a retrospective single centre controlled study. Journal of Experimental & Clinical Cancer Research 2009; 28(1) doi: 10.1186/1756-9966-28-142
|
| 13 |
Timothy R. Morgan. Clinical Cancer Prevention. Recent Results in Cancer Research 2010; 188 doi: 10.1007/978-3-642-10858-7_7
|
| 14 |
YAO LIU, LI JIANG, YI MU. Somatostatin receptor subtypes 2 and 5 are associated with better survival in operable hepatitis B-related hepatocellular carcinoma following octreotide long-acting release treatment. Oncology Letters 2013; 6(3) doi: 10.3892/ol.2013.1435
|
| 15 |
Romain Eychenne, Christelle Bouvry, Mickael Bourgeois, Pascal Loyer, Eric Benoist, Nicolas Lepareur. Overview of Radiolabeled Somatostatin Analogs for Cancer Imaging and Therapy. Molecules 2020; 25(17) doi: 10.3390/molecules25174012
|
| 16 |
Ioulia Evangelou, Constantina Petraki, Pavlos Msaouel, Andreas Scorilas, Eleni Sdrolia, Georgia Padazi, Vassilios Koborozos, Michael Koutsilieris. Immunohistochemical expression of somatostatin receptor subtypes 2 and 5 in colorectal cancer. European Journal of Clinical Investigation 2012; 42(7) doi: 10.1111/j.1365-2362.2012.02648.x
|
| 17 |
Elias Kouroumalis, Ioannis Tsomidis, Argryro Voumvouraki. Is There a Place for Somatostatin Analogues for the Systemic Treatment of Hepatocellular Carcinoma in the Immunotherapy Era?. Livers 2022; 2(4) doi: 10.3390/livers2040024
|
| 18 |
Hanna K. Sanoff, Richard Kim, Anastasia Ivanova, Angela Alistar, Autumn J. McRee, Bert H. O’Neil. Everolimus and pasireotide for advanced and metastatic hepatocellular carcinoma. Investigational New Drugs 2015; 33(2) doi: 10.1007/s10637-015-0209-7
|
| 19 |
Xi Chen, Xiao-Yu Zhang, Yang Shen, Li-Li Fan, Mu-Lan Ren, Yong-Ping Wu. Synthetic paclitaxel-octreotide conjugate reversing the resistance of A2780/Taxol to paclitaxel in xenografted tumor in nude mice. Oncotarget 2016; 7(50) doi: 10.18632/oncotarget.13120
|
| 20 |
S. Massironi, M. Fraquelli, S. Paggi, A. Sangiovanni, D. Conte, V. Sciola, C. Ciafardini, M. Colombo, M. Peracchi. Chromogranin A levels in chronic liver disease and hepatocellular carcinoma. Digestive and Liver Disease 2009; 41(1) doi: 10.1016/j.dld.2008.05.002
|
| 21 |
Li Su, WenFang Xu. Peptidomimetics and metalloprotease inhibitors as anticancer drugs. Science in China Series B: Chemistry 2009; 52(5) doi: 10.1007/s11426-009-0040-0
|
| 22 |
Nuh N. Rahbari, Arianeb Mehrabi, Nathan M. Mollberg, Sascha A. Müller, Moritz Koch, Markus W. Büchler, Jürgen Weitz. Hepatocellular Carcinoma. Annals of Surgery 2011; 253(3) doi: 10.1097/SLA.0b013e31820d944f
|
| 23 |
Hendrik Reynaert, Isabelle Colle. Treatment of Advanced Hepatocellular Carcinoma with Somatostatin Analogues: A Review of the Literature. International Journal of Molecular Sciences 2019; 20(19) doi: 10.3390/ijms20194811
|
| 24 |
Argyrios Periferakis, Georgios Tsigas, Aristodemos-Theodoros Periferakis, Ioana Anca Badarau, Andreea-Elena Scheau, Mircea Tampa, Simona Roxana Georgescu, Andreea Cristiana Didilescu, Cristian Scheau, Constantin Caruntu, Maria Beatrice Morelli. Antitumoral and Anti-inflammatory Roles of Somatostatin and Its Analogs in Hepatocellular Carcinoma. Analytical Cellular Pathology 2021; 2021 doi: 10.1155/2021/1840069
|
| 25 |
Hao-Wen Sim, Jennifer Knox, Laura A. Dawson. An Update on Randomized Clinical Trials in Hepatocellular Carcinoma. Surgical Oncology Clinics of North America 2017; 26(4) doi: 10.1016/j.soc.2017.05.006
|
| 26 |
Kerstin Wohlleber, Patrick Heger, Pascal Probst, Christoph Engel, Markus K. Diener, André L. Mihaljevic. Health-related quality of life in primary hepatic cancer: a systematic review assessing the methodological properties of instruments and a meta-analysis comparing treatment strategies. Quality of Life Research 2021; 30(9) doi: 10.1007/s11136-021-02810-8
|
| 27 |
Omar Abdel-Rahman, Angela Lamarca, Juan W Valle, Richard A Hubner. Somatostatin receptor expression in hepatocellular carcinoma: prognostic and therapeutic considerations. Endocrine-Related Cancer 2014; 21(6) doi: 10.1530/ERC-14-0389
|
| 28 |
Jean-Claude Barbare, Olivier Bouché, Franck Bonnetain, Laetitia Dahan, Catherine Lombard-Bohas, Roger Faroux, Jean-Luc Raoul, Stéphane Cattan, Alain Lemoine, Jean-Frédéric Blanc, Jean-Pierre Bronowicki, Jean-Pierre Zarski, Sophie Cazorla, Dany Gargot, Thierry Thevenot, Emmanuel Diaz, Anne Bastie, Thomas Aparicio, Laurent Bedenne. Treatment of advanced hepatocellular carcinoma with long-acting octreotide: A phase III multicentre, randomised, double blind placebo-controlled study. European Journal of Cancer 2009; 45(10) doi: 10.1016/j.ejca.2009.02.018
|
| 29 |
Maria Cristina De Martino, Leo J. Hofland, Steven W.J. Lamberts. Neuroendocrinology - Pathological Situations and Diseases. Progress in Brain Research 2010; 182 doi: 10.1016/S0079-6123(10)82011-4
|
| 30 |
Malgorzata Trofimiuk‐Müldner, Alicja Hubalewska‐Dydejczyk. Somatostatin Analogues. 2015; doi: 10.1002/9781119031659.ch12
|
| 31 |
Monica Marra, Ignazio M Sordelli, Angela Lombardi, Monica Lamberti, Luciano Tarantino, Aldo Giudice, Paola Stiuso, Alberto Abbruzzese, Rossella Sperlongano, Marina Accardo, Massimo Agresti, Michele Caraglia, Pasquale Sperlongano. Molecular targets and oxidative stress biomarkers in hepatocellular carcinoma: an overview. Journal of Translational Medicine 2011; 9(1) doi: 10.1186/1479-5876-9-171
|
| 32 |
Jordi Rodon, Victoria DeSantos, Robert Jean Ferry, Razelle Kurzrock. Early drug development of inhibitors of the insulin-like growth factor-I receptor pathway: Lessons from the first clinical trials. Molecular Cancer Therapeutics 2008; 7(9) doi: 10.1158/1535-7163.MCT-08-0265
|
| 33 |
Xi-Qing Ji, Xin-Jian Ruan, Hong Chen, Gang Chen, Shi-Yong Li, Bo Yu. Somatostatin analogues in advanced hepatocellular carcinoma: An updated systematic review and meta-analysis of randomized controlled trials. Medical Science Monitor 2011; 17(8) doi: 10.12659/MSM.881892
|
| 34 |
Tian-Kang Guo, Xiang-Yong Hao, Bin Ma, Ke-Hu Yang, Yi-Ping Li, Hong-Ling Li, Yuan-Hui Gu, Hui Cai, Ya-Li Liu, Yuan Li, Wei-Peng Zhan. Octreotide for advanced hepatocellular carcinoma: a meta-analysis of randomized controlled trials. Journal of Cancer Research and Clinical Oncology 2009; 135(12) doi: 10.1007/s00432-009-0615-3
|
| 35 |
Marialuisa Appetecchia, Roberto Baldelli. Somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine tumours, current aspects and new perspectives. Journal of Experimental & Clinical Cancer Research 2010; 29(1) doi: 10.1186/1756-9966-29-19
|
| 36 |
Chapter 4: Chemotherapy and radiotherapy. Hepatology Research 2010; 40(s1) doi: 10.1111/j.1872-034X.2010.00657.x
|
| 37 |
Dimitrios N. Samonakis, George Notas, Nikolaos Christodoulakis, Elias A. Kouroumalis. Mechanisms of Action and Resistance of Somatostatin Analogues for the Treatment of Hepatocellular Carcinoma: A Message Not Well Taken. Digestive Diseases and Sciences 2008; 53(9) doi: 10.1007/s10620-007-0175-9
|
| 38 |
Giuseppe Cabibbo, Marco Enea, Massimo Attanasio, Jordi Bruix, Antonio Craxì, Calogero Cammà. A meta‐analysis of survival rates of untreated patients in randomized clinical trials of hepatocellular carcinoma†. Hepatology 2010; 51(4) doi: 10.1002/hep.23485
|
| 39 |
Pavlos Msaouel, Evanthia Galanis, Michael Koutsilieris. Somatostatin and somatostatin receptors: implications for neoplastic growth and cancer biology. Expert Opinion on Investigational Drugs 2009; 18(9) doi: 10.1517/13543780903176399
|
| 40 |
Daniel Kaemmerer, Robin Schindler, Franziska Mußbach, Uta Dahmen, Annelore Altendorf-Hofmann, Olaf Dirsch, Jörg Sänger, Stefan Schulz, Amelie Lupp. Somatostatin and CXCR4 chemokine receptor expression in hepatocellular and cholangiocellular carcinomas: tumor capillaries as promising targets. BMC Cancer 2017; 17(1) doi: 10.1186/s12885-017-3911-3
|
| 41 |
G. Treiber, T. Wex, P. Malfertheiner. Impact of different anticancer regimens on biomarkers of angiogenesis in patients with advanced hepatocellular cancer. Journal of Cancer Research and Clinical Oncology 2009; 135(2) doi: 10.1007/s00432-008-0443-x
|
| 42 |
Wei-Dong Jia, Ge-Liang Xu, Wei Wang, Zhi-Hua Wang, Jian-Sheng Li, Jin-Liang Ma, Wei-Hua Ren, Yong-Sheng Ge, Ji-Hai Yu, Wen-Bin Liu. A Somatostatin Analogue, Octreotide, Inhibits the Occurrence of Second Primary Tumors and Lung Metastasis after Resection of Hepatocellular Carcinoma in Mice. The Tohoku Journal of Experimental Medicine 2009; 218(2) doi: 10.1620/tjem.218.155
|
| 43 |
Simone Krebs, Mark Dunphy. Blumgart's Surgery of the Liver, Biliary Tract and Pancreas, 2-Volume Set. 2017; doi: 10.1016/B978-0-323-34062-5.00017-0
|